On June 20, 2025, Moleculin Biotech, Inc. announced a public offering of approximately 9.97 million shares and warrants, expecting to raise around $5.9 million, with potential to reach $17.8 million if warrants are fully exercised. The offering will support clinical development of its drug portfolios.